NCT07466160

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

A Multi-center, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of 7MW3711 in Combination With JS207 With or Without Chemotheray in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.

Detailed description

A Multi-center, Open-label, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of 7MW3711 in Combination With JS207 with or without Chemotheray in Patients With Advanced Solid Tumors.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	7MW3711	7MW3711 will be administered as IV infusion.
DRUG	JS207	JS207 will be administered as IV infusion.
DRUG	Cisplatin	Cisplatin will be administered as IV infusion.
DRUG	Carboplatin	Carboplatin will be administered as IV infusion.

Timeline

• Start date: 2026-02-11
• Primary completion: 2027-12-31
• Completion: 2029-12-31
• First posted: 2026-03-12
• Last updated: 2026-03-12

Locations

1 site across 1 country: China